以吸附无细胞百日咳-白喉-破伤风疫苗为基础的联合疫苗研究进展

发布时间：2018-07-22 17:34

【摘要】：吸附无细胞百日咳疫苗、白喉和破伤风类毒素联合疫苗(Adsorbed Acellular Pertussis Vaccine,Diphtheria ToxoidTetanus Toxoid Combined Vaccine,DTaP)已有30多年的使用历史。将DTaP与乙型肝炎疫苗(Hepatitis B Vaccine,HepB)、脊髓灰质炎灭活疫苗(Inactivated Poliovirus Vaccine,IPV)和b型流行性感冒嗜血杆菌结合疫苗(Haemophilus Influenzae Type b Conjugate Vaccine,Hib)等制备成为联合疫苗使用,可以减少接种剂次,提高受种者的依从性,从而提高疫苗接种率。但是,联合疫苗不是几种疫苗简单地混合,在将DTaP与其他疫苗联合的过程中面临许多技术挑战,如DTaP与Hib联合存在Hib免疫原性降低的问题,DTaP与HepB联合存在免疫程序不统一和HepB免疫持久性的问题,DTaP与IPV联合时,其中的防腐剂柳硫汞会降低IPV的免疫原性的问题等。现就DTaP与这些疫苗联合时所面临的技术挑战、目前的研究进展和未来发展方向作一综述。
[Abstract]:The adsorption of acellular pertussis vaccine, diphtheria pertussis vaccine Diphtheria ToxoidTetanus Toxoid combined Vaccine TaP (DTaP) has been used for more than 30 years. DTaP, hepatitis B vaccine (HepB), inactivated Poliovirus vaccine (Inactivated Poliovirus vaccine IPV) and Haemophilus Influenzae Type b Conjugate Vaccine Vaccine Hib (Haemophilus Influenzae Type b Vaccine Hib) were prepared as combined vaccines. So as to improve the vaccination rate. However, the combined vaccine is not a simple mix of several vaccines, and there are many technical challenges in combining DTaP with other vaccines. For example, if DTaP and Hib combined with Hib have lower Hib immunogenicity, DTaP and HepB have the problems of inconsistent immunization procedures and HepB immune persistence. When DTaP and IPV are combined, the preservative salthimercury will reduce the immunogenicity of IPV, and so on. In this paper, the technical challenges faced by DTaP combined with these vaccines, the current research progress and the future development direction are reviewed.
【作者单位】：中国医学科学院北京协和医学院医学生物学研究所;
【基金】：国家“重大新药创制”科学技术重大专项(编号:2012ZX09101318) 云南省科学技术创新强省计划(编号:2007AD015)
【分类号】：R392.1

【相似文献】